<abstract xmlns="http://www.w3.org/1999/xhtml"><p> Patients with haemophilia have benefited hugely from the advances in basic science achieved over the past 50 years. The introduction of clotting factor concentrates opened the door to home treatment and the subsequent availability of plasma and then recombinant products heralded the prophylaxis era. As clinicians and patients begin to manage the introduction of longer-acting factor concentrates, there are also many novel therapies and approaches in development, many of which offer the potential to transform the lives for individuals with inherited bleeding disorders and their families.</p></abstract>

Patients with haemophilia have benefited hugely from the advances in basic science achieved over the past 50 years. The introduction of clotting factor concentrates opened the door to home treatment and the subsequent availability of plasma and then recombinant products heralded the prophylaxis era. As clinicians and patients begin to manage the introduction of longer-acting factor concentrates, there are also many novel therapies and approaches in development, many of which offer the potential to transform the lives for individuals with inherited bleeding disorders and their families.

Into the future with novel emerging therapies for haemophilia

The Journal of Haemophilia Practice

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

{"article-title":"Into the future with novel emerging therapies for haemophilia"}

Patients with haemophilia have benefited hugely from the advances in basic science achieved over the past 50 years. The introduction of clotting factor...

Into the future with novel emerging therapies for haemophilia

Article Category: Kd50: Comprehensive Care

Publié en ligne: 21 avr. 2018

Pages: 24 - 25

DOI: https://doi.org/10.17225/jhp00057

Mots clés
haemophilia, Katharine Dormandy, clotting factor, novel therapies

© 2018

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Into the future with novel emerging therapies for haemophilia

Article Category: Kd50: Comprehensive Care

Publié en ligne: 21 avr. 2018

Pages: 24 - 25

DOI: https://doi.org/10.17225/jhp00057

Mots cléshaemophilia, Katharine Dormandy, clotting factor, novel therapies

© 2018

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Mots clés
haemophilia, Katharine Dormandy, clotting factor, novel therapies